Wedbush reiterated their outperform rating on shares of Stemline Therapeutics Inc (NASDAQ:STML) in a research report released on Friday morning. The brokerage currently has a $11.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on STML. HC Wainwright set a $34.00 target price on Stemline Therapeutics and gave the company a buy rating in a report on Sunday, January 8th. Jefferies Group LLC set a $23.00 target price on Stemline Therapeutics and gave the company a buy rating in a report on Sunday, December 4th. Roth Capital reiterated a buy rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Wednesday, December 7th. Zacks Investment Research upgraded Stemline Therapeutics from a sell rating to a hold rating in a report on Thursday, February 9th. Finally, Ladenburg Thalmann Financial Services reiterated a buy rating on shares of Stemline Therapeutics in a report on Monday, February 6th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Stemline Therapeutics presently has an average rating of Buy and a consensus target price of $21.00.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 0.53% on Friday, hitting $9.45. The stock had a trading volume of 135,579 shares. Stemline Therapeutics has a 12-month low of $4.06 and a 12-month high of $14.60. The company’s market cap is $168.64 million. The stock has a 50 day moving average price of $7.91 and a 200-day moving average price of $10.57.

Your IP Address:

In other Stemline Therapeutics news, insider David Gionco sold 3,593 shares of Stemline Therapeutics stock in a transaction dated Thursday, January 19th. The stock was sold at an average price of $11.46, for a total transaction of $41,175.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ivan Bergstein sold 17,980 shares of Stemline Therapeutics stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total value of $125,680.20. The disclosure for this sale can be found here. Insiders have sold a total of 65,356 shares of company stock valued at $531,879 over the last ninety days. 16.70% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in shares of Stemline Therapeutics during the third quarter worth about $400,000. State Treasurer State of Michigan acquired a new stake in shares of Stemline Therapeutics during the third quarter worth about $217,000. Oak Ridge Investments LLC increased its stake in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares during the period. Columbus Circle Investors acquired a new stake in shares of Stemline Therapeutics during the third quarter worth about $1,577,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Stemline Therapeutics during the third quarter worth about $3,612,000. 37.76% of the stock is owned by institutional investors.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.